Impact of COVID-19 vaccination on the use of PD-1 inhibitor in treating patients with cancer: a real-world study

• DOI: 10.1136/jitc-2021-004157
• Publication Date: 2022-03-09T16:17:46Z
• Authors: Qi Mei; Guangyuan Hu; Yang Yang; Bo Liu; Junping Yin; Ming Li; Qiao Huang; Xi Tang; Alexander Böhner; Amy Bryant; Christian Kurts; Xianglin Yuan; Jian Li
• Keywords: Subgroup analysis

Anti-COVID-19 vaccination may have functional implications for immune checkpoint inhibitor treatment in patients with cancer. This study was undertaken to determine whether the safety or efficacy of anti-PD-1 therapy is reduced cancer during COVID-19 vaccination. A large multicenter observational conducted 83 Chinese hospitals between January 28, 2021 and September 30, 2021. total 3552 were screened 2048 eligible receiving PD-1 recruited. All enrolled had received camrelizumab alone conjunction other therapies. Among these, 1518 (74.1%) BBIBP-CorV vaccine defined as vaccinated subgroup. The remaining 530 (25.9%) did not receive anti-COVID-19 non-vaccinated For all participants, Response Evaluation Criteria Solid Tumor Common Terminology Adverse Events criteria used evaluate treatment, respectively. Propensity score match analysis optimal pair matching compare these subgroups. included (median age 59 years, 27.6% female). Most (98.8%) metastatic lung, liver intestinal tract. Aside from 55.9% additional only mild side effects reported. a statistically greater percentage comorbidities. After age, gender, stage/types, comorbidity performance status, 1060 (530 pairs) selected propensity analysis. showed no significant differences overall response rate (25.3% vs 28.9%, p=0.213) disease control (64.6% 67.0%, p=0.437) Immune-related adverse events (irAEs) reported both subgroups after treatment. who experienced irAEs, median interval first dose shot ≤16 days. Compared subgroup, irAEs more frequently (grade 1 2 irAEs; 33.8% 19.8%, p<0.001) less likely discontinue (4.2% 20.4%, p<0.001). Severe 3 irAE higher) related reported, however frequency such observed vaccine, BBIBP-CorV, increase severe anti-PD-1-related nor it reduce clinical Thus, we conclude that need suspend